Summary

The market for rapid microbiology testing is projected to grow from USD 5.69 billion in 2026 to USD 9.00 billion by 2031, reflecting a CAGR of 9.6%. Market growth is supported by rising pharmaceutical and biopharmaceutical production, stringent sterility and contamination control requirements, and expanding use of molecular diagnostics and automated microbiology systems. Additionally, advancements in Polymerase Chain Reaction (PCR), mass spectrometry, and rapid microbial identification technologies are improving laboratory efficiency and supporting broader adoption globally.

"By product, reagents & Kits segment to showcase highest CAGR during forecast period”
The growth of the reagents & kits segment is primarily driven by the recurring demand for culture media, assay kits, primers, probes, stains, buffers, and antimicrobial susceptibility testing reagents used in rapid microbiology workflows. Rising incidences of infectious diseases and increasing emphasis on sterility assurance and contamination control are accelerating testing volumes across hospitals, pharmaceutical & biotechnology companies, and food testing laboratories. Additionally, expanding adoption of molecular microbiology techniques, automated testing platforms, and rapid PCR-based assays is expected to further drive demand for reagents & kits throughout the forecast period.
“By method, growth-based segment to hold the largest share of rapid microbiology testing market in 2026"
A growth-based rapid microbiology testing method is likely to dominate the market in 2026 due to its extensive use in pharmaceutical sterility testing, environmental monitoring, food safety testing, and clinical microbiology workflows. Growth-based rapid microbiology methods are widely adopted because they provide reliable detection of viable microorganisms while supporting regulatory compliance and quality assurance requirements. The increasing adoption of automated microbial detection systems, rising demand for faster contamination identification, and growing pharmaceutical and biopharmaceutical manufacturing activities are further driving segment growth. Additionally, the need for rapid product release and improved laboratory efficiency continues to support demand for growth-based testing methods.
"Asia Pacific to register fastest growth rate in rapid microbiology testing market during forecast period"
The region is witnessing significant growth due to expanding healthcare infrastructure, increasing healthcare expenditure, and rapid modernization of hospitals, diagnostic laboratories, and pharmaceutical manufacturing facilities. Rising prevalence of infectious diseases and growing awareness regarding contamination control and patient safety are increasing the demand for rapid microbial diagnostics across the region. Additionally, increasing investments in biotechnology research, biopharmaceutical production, and laboratory automation are further supporting market expansion. The growing adoption of molecular diagnostics, rapid PCR systems, and automated microbial identification technologies is also contributing to market growth. Major countries driving regional expansion include China, India, Japan, and South Korea.
Breakdown of primary participants in the rapid microbiology testing market is as follows:
・By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%)
・By Designation: C-level Executives (27%), Directors (18%), and Other Designations (55%)
・By Region: North America (51%), Europe (21%), Asia Pacific (18%), Latin America (6%), and the Middle East & Africa (4%)

The key players in the rapid microbiology testing market are bioMérieux (France), Waters Corporation (US), Danaher Corporation (US), Abbott Laboratories (US), Thermo Fisher Scientific, Inc. (US), Bruker Corporation (US), QuidelOrtho Corporation (US), Sartorius AG (Germany), Merck KGaA (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Charles River Laboratories International, Inc. (US), Neogen Corporation (US), Bio-Rad Laboratories, Inc. (US), Shimadzu Corporation (Japan), and Rapid Micro Biosystems, Inc. (US).

Research Coverage:
This research report categorizes the rapid microbiology testing market by product (consumables, instruments, reagents & kits), method (growth-based, cellular component-based, nucleic acid-based, viability-based, and other methods) application (industrial testing, clinical disease diagnosis, and research applications), end user (hospitals, clinical laboratories, & ASCs; pharmaceutical & biotechnology companies; food & beverage companies; environmental & water testing laboratories; and other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa).
The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the rapid microbiology testing market. A detailed analysis of key industry players has been conducted to provide insights into their business overview, solutions, and key strategies, such as partnerships, collaborations, expansions, agreements, product launches, and recent developments in the rapid microbiology testing market. This report covers the competitive analysis of upcoming startups in the rapid microbiology testing ecosystem.

Reasons to Buy This Report:
The report will help leaders/new entrants in this market by providing information on the closest approximations of revenue for the overall rapid microbiology testing market and its subsegments. This report will help stakeholders understand the competitive landscape and gain deeper insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
・Analysis of key drivers (increasing burden of healthcare-associated infections (HAIs), antimicrobial resistance (AMR), and infectious diseases; technological advancements in automated microbiology and MALDI-TOF platforms; growing food safety concerns and rising incidence of foodborne illnesses; increasing R&D activities in microbiology and infectious disease), restraints (high capital investments and low cost-benefit ratio, unfavorable regulatory and reimbursement scenario, shortage of skilled personnel), opportunities (growing demand for rapid microbiology testing in emerging economies, expansion of rapid microbial testing applications), and challenges (operational barriers, high investment for automated microbial identification systems)
・Product development/innovation: Detailed insights on upcoming technologies, research & development activities, and product launches in the rapid microbiology testing market.
・Market development: Comprehensive information about lucrative markets; the report analyzes the rapid microbiology testing market across varied regions.
・Market diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the rapid microbiology testing market.
・Competitive assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like bioMérieux (France), Waters Corporation (US), Danaher Corporation (US), Abbott Laboratories (US), and Thermo Fisher Scientific, Inc. (US).

ページTOPに戻る

Table of Contents

1 INTRODUCTION 39
1.1 STUDY OBJECTIVES 39
1.2 MARKET DEFINITION 39
1.3 STUDY SCOPE 40
1.3.1 MARKETS COVERED AND REGIONAL SCOPE 40
1.3.2 INCLUSIONS AND EXCLUSIONS 41
1.3.3 YEARS CONSIDERED 42
1.3.4 CURRENCY CONSIDERED 42
1.4 STAKEHOLDERS 42
1.5 SUMMARY OF CHANGES 43
2 EXECUTIVE SUMMARY 44
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 44
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 45
2.3 DISRUPTIVE TRENDS SHAPING MARKET 46
2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS 47
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 48
3 PREMIUM INSIGHTS 49
3.1 RAPID MICROBIOLOGY TESTING MARKET OVERVIEW 49
3.2 RAPID MICROBIOLOGY TESTING MARKET, BY PRODUCT, 2026 VS. 2031 50
3.3 RAPID MICROBIOLOGY TESTING MARKET, BY METHOD, 2026 VS. 2031 50
3.4 RAPID MICROBIOLOGY TESTING MARKET, BY APPLICATION, 2026 VS. 2031 51
3.5 RAPID MICROBIOLOGY TESTING MARKET, BY END USER, 2026 VS. 2031 51
3.6 RAPID MICROBIOLOGY TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 52
4 MARKET OVERVIEW 53
4.1 INTRODUCTION 53
4.2 MARKET DYNAMICS 53
4.2.1 DRIVERS 54
4.2.1.1 Increasing burden of healthcare-associated infections (HAIs), antimicrobial resistance (AMR), and infectious diseases 54
4.2.1.2 Technological advancements in automated microbiology and
MALDI-TOF platforms 55
4.2.1.3 Growing food safety concerns and rising incidence of foodborne illnesses 56
4.2.1.4 Increasing R&D in microbiology and infectious diseases 57
 
4.2.2 RESTRAINTS 58
4.2.2.1 High capital investments and low cost-benefit ratio 58
4.2.2.2 Unfavorable regulatory and reimbursement scenario 58
4.2.2.3 Shortage of skilled personnel 58
4.2.3 OPPORTUNITIES 59
4.2.3.1 Growing demand for rapid microbiology testing in emerging economies 59
4.2.3.2 Expansion of rapid microbial testing applications 59
4.2.4 CHALLENGES 60
4.2.4.1 Operational barriers 60
4.2.4.2 High investment for automated microbial identification systems 60
4.3 UNMET NEEDS AND WHITE SPACES 61
4.3.1 UNMET NEEDS IN RAPID MICROBIOLOGY TESTING MARKET 61
4.3.2 WHITE SPACE OPPORTUNITIES 62
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 63
4.4.1 INTERCONNECTED MARKETS 63
4.4.2 CROSS-SECTOR OPPORTUNITIES 64
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 65
4.5.1 KEY MOVES AND STRATEGIC FOCUS 65
5 INDUSTRY TRENDS 66
5.1 PORTER’S FIVE FORCES ANALYSIS 66
5.1.1 BARGAINING POWER OF SUPPLIERS 67
5.1.2 BARGAINING POWER OF BUYERS 67
5.1.3 THREAT OF NEW ENTRANTS 67
5.1.4 THREAT OF SUBSTITUTES 67
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 67
5.2 MACROECONOMIC INDICATORS 68
5.2.1 INTRODUCTION 68
5.2.2 GDP TRENDS AND FORECAST 68
5.3 SUPPLY CHAIN ANALYSIS 71
5.4 VALUE CHAIN ANALYSIS 72
5.5 ECOSYSTEM ANALYSIS 74
5.5.1 RAPID MICROBIOLOGY TESTING MARKET: ROLE OF COMPANIES IN ECOSYSTEM 75
5.6 PRICING ANALYSIS 75
5.6.1 AVERAGE SELLING PRICE OF RAPID MICROBIOLOGY TESTING PRODUCTS,
BY KEY PLAYER, 2024–2026 76
5.6.2 AVERAGE SELLING PRICE OF RAPID MICROBIOLOGY TESTING PRODUCTS,
BY REGION, 2024–2026 76
5.7 TRADE ANALYSIS 77
5.7.1 IMPORT SCENARIO (HS CODE 3822) 78
5.7.2 EXPORT SCENARIO (HS CODE 3822) 78
5.8 KEY CONFERENCES & EVENTS, 2026–2027 79
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 79
5.10 INVESTMENT & FUNDING SCENARIO 80
5.11 CASE STUDY ANALYSIS 81
5.11.1 YOUNGS SEAFOOD ACCELERATED FOOD TESTING WITH VIDAS 81
5.11.2 RAPID MICROBIOLOGICAL METHOD CASE STUDY FOR ADVANCED THERAPY MEDICINAL PRODUCTS 81
5.11.3 RAPID DETECTION METHOD OF BACTERIAL PATHOGENS IN SURFACE WATERS AND NEW RISK INDICATOR FOR WATER PATHOGENIC POLLUTION 82
5.12 IMPACT OF US TARIFFS—RAPID MICROBIOLOGY TESTING MARKET 82
5.12.1 INTRODUCTION 82
5.12.2 KEY TARIFF RATES 83
5.12.3 PRICE IMPACT ANALYSIS 83
5.12.4 IMPACT ON COUNTRIES/REGIONS 84
5.12.4.1 North America 84
5.12.4.2 Europe 84
5.12.4.3 Asia Pacific 84
5.12.5 IMPACT ON END-USE INDUSTRIES 84
5.12.5.1 Hospitals, Clinical Laboratories, and ASCs 84
5.12.5.2 Pharmaceutical & Biotechnology Companies 85
5.12.5.3 Food & Beverage Companies 85
5.12.5.4 Environmental & Water Testing Laboratories 85
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 86
6.1 KEY EMERGING TECHNOLOGIES 86
6.1.1 AUTOMATED MULTIPLEX PCR SYSTEMS 86
6.1.2 BIOSENSORS 86
6.2 COMPLEMENTARY TECHNOLOGIES 86
6.2.1 OPTICAL IMMUNOSENSORS 86
6.2.2 ELECTROCHEMICAL IMMUNOSENSORS 87
6.3 ADJACENT TECHNOLOGIES 87
6.3.1 DIGITAL PCR (DPCR) 87
6.4 TECHNOLOGY/PRODUCT ROADMAP 87
6.5 PATENT ANALYSIS 88
6.5.1 LIST OF MAJOR PATENTS 89
6.6 FUTURE APPLICATIONS 90
6.7 IMPACT OF AI/GENERATIVE AI ON RAPID MICROBIOLOGY TESTING MARKET 90
6.7.1 INTRODUCTION 90
6.7.2 TOP USE CASES AND MARKET POTENTIAL 91
6.7.3 KEY COMPANIES IMPLEMENTING AI 91
6.7.4 FUTURE OF AI 92
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 93
7.1 REGIONAL REGULATIONS AND COMPLIANCE 93
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93
7.1.2 INDUSTRY STANDARDS 95
7.2 SUSTAINABILITY INITIATIVES 96
7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN RAPID MICROBIOLOGY TESTING 96
7.2.1.1 Eco-friendly Initiatives 97
7.3 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES 98
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 99
8.1 DECISION-MAKING PROCESS 99
8.2 KEY STAKEHOLDERS AND BUYING EVALUATION CRITERIA 99
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 99
8.2.2 BUYING CRITERIA 100
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 101
8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 102
8.5 MARKET PROFITABILITY 103
8.5.1 REVENUE POTENTIAL 103
8.5.2 COST DYNAMICS 104
8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 104
9 RAPID MICROBIOLOGY TESTING MARKET, BY PRODUCT 106
9.1 INTRODUCTION 107
9.2 INSTRUMENTS 107
9.2.1 AUTOMATED MICROBIAL IDENTIFICATION & ANTIMICROBIAL SUSCEPTIBILITY TESTING SYSTEMS 112
9.2.1.1 Ease of use compared to conventional identification processes to support market growth 112
9.2.2 MASS SPECTROMETERS 115
9.2.2.1 Rapid results associated with mass spectrometry methods to boost adoption 115
9.2.3 BIOLUMINESCENCE & FLUORESCENCE-BASED DETECTION SYSTEMS 118
9.2.3.1 Unwanted detection of non-microbial ATP to limit market adoption 118
9.2.4 PCR SYSTEMS 121
9.2.4.1 Growing use of standard, real-time, and qPCR for rapid microbial testing to support growth 121
9.2.5 CYTOMETERS 124
9.2.5.1 Ability to detect viable organisms to favor market growth 124
9.2.6 ACTIVE AIR SAMPLERS 127
9.2.6.1 Convenience and ease of use to drive demand for active air samplers 127
9.2.7 OTHER INSTRUMENTS 130
9.3 REAGENTS & KITS 133
9.3.1 STERILITY TESTING REAGENTS & KITS 136
9.3.1.1 Increasing adoption of BET assays to propel market growth 136
9.3.2 OTHER REAGENTS & KITS 139
9.4 CONSUMABLES 142
9.4.1 DEVELOPMENT OF AUTOMATED ZONE READERS AND DISPENSERS TO DRIVE MARKET GROWTH 142
10 RAPID MICROBIOLOGY TESTING MARKET: VOLUME ANALYSIS 146
10.1 INTRODUCTION 146
10.2 GLOBAL: VOLUME OF MALDI-TOF MS MICROBIAL IDENTIFICATION SYSTEM
INSTALLED BASE 146
11 RAPID MICROBIOLOGY TESTING MARKET, BY METHOD 147
11.1 INTRODUCTION 148
11.2 GROWTH-BASED RAPID MICROBIOLOGY TESTING 149
11.2.1 RISING DEMAND FOR GROWTH-BASED TESTING TO DRIVE MARKET 149
11.3 CELLULAR COMPONENT-BASED RAPID MICROBIOLOGY TESTING 152
11.3.1 HIGH SENSITIVITY, ACCURACY, AND SPECIFICITY OF CELLULAR COMPONENT-BASED METHODS TO BOOST MARKET 152
11.4 NUCLEIC ACID-BASED RAPID MICROBIOLOGY TESTING 155
11.4.1 HIGH ACCURACY ASSOCIATED WITH NUCLEIC ACID-BASED METHODS TO FAVOR MARKET GROWTH 155
11.5 VIABILITY-BASED RAPID MICROBIOLOGY TESTING 158
11.5.1 NEAR REAL-TIME DETECTION AND IMPROVED ACCURACY TO DRIVE DEMAND 158
11.6 OTHER METHODS 161
12 RAPID MICROBIOLOGY TESTING MARKET, BY APPLICATION 165
12.1 INTRODUCTION 166
12.2 INDUSTRIAL TESTING 166
12.2.1 FOOD & BEVERAGE TESTING 170
12.2.1.1 Stringent quality control and quality assurance processes to drive market growth 170
12.2.2 PHARMACEUTICAL & BIOLOGICAL DRUG TESTING 173
12.2.2.1 Improved regulatory scenario for drug development to support market growth 173
12.2.3 ENVIRONMENTAL TESTING 177
12.2.3.1 Growing focus on environmental monitoring to boost segmental growth 177
12.2.4 COSMETIC & PERSONAL CARE PRODUCTS TESTING 180
12.2.4.1 Growing use of rapid microbiology testing to determine the presence of microbes favors market growth 180
12.2.5 OTHER INDUSTRIAL TESTING APPLICATIONS 184
 
12.3 CLINICAL DISEASE DIAGNOSIS 187
12.3.1 HIGH BURDEN OF INFECTIOUS DISEASES AND HEALTHCARE-ASSOCIATED INFECTIONS TO PROPEL MARKET GROWTH 187
12.4 RESEARCH 191
12.4.1 INCREASING NUMBER OF EPIDEMIOLOGY-BASED RESEARCH STUDIES TO DRIVE MARKET GROWTH 191
13 RAPID MICROBIOLOGY TESTING MARKET, BY END USER 195
13.1 INTRODUCTION 196
13.2 HOSPITALS, CLINICAL LABORATORIES, AND ASCS 196
13.2.1 INCREASING PATIENT VOLUME AND RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET 196
13.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 200
13.3.1 STRINGENT GMP AND CONTAMINATION CONTROL REQUIREMENTS TO DRIVE TESTING DEMAND 200
13.4 FOOD & BEVERAGE COMPANIES 203
13.4.1 STRINGENT FOOD SAFETY REGULATIONS AND QUALITY CONTROL TO SUPPORT MARKET GROWTH 203
13.5 ENVIRONMENTAL & WATER TESTING LABORATORIES 206
13.5.1 GROWING FOCUS ON WATER SAFETY AND ENVIRONMENTAL MONITORING TO DRIVE DEMAND 206
13.6 OTHER END USERS 210
14 RAPID MICROBIOLOGY TESTING MARKET, BY REGION 214
14.1 INTRODUCTION 215
14.2 NORTH AMERICA 215
14.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 216
14.2.2 US 221
14.2.2.1 Increasing prevalence of infectious diseases to drive market 221
14.2.3 CANADA 225
14.2.3.1 Supportive government initiatives and increased research funding to boost market 225
14.3 EUROPE 230
14.3.1 EUROPE: MACROECONOMIC OUTLOOK 230
14.3.2 GERMANY 234
14.3.2.1 Favorable government policies to propel market 234
14.3.3 FRANCE 239
14.3.3.1 Favorable healthcare reforms and investments in diagnostic infrastructure to drive market 239
14.3.4 UK 242
14.3.4.1 Emphasis on food contamination monitoring and hygiene controls to drive market 242
14.3.5 ITALY 246
14.3.5.1 Improved healthcare services and better disease surveillance to support market growth 246
14.3.6 SPAIN 251
14.3.6.1 Water monitoring mandate to boost market growth 251
14.3.7 RUSSIA 255
14.3.7.1 Strengthening water quality surveillance and outbreak response drives adoption in Russia 255
14.3.8 REST OF EUROPE 259
14.4 ASIA PACIFIC 263
14.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK 263
14.4.2 CHINA 267
14.4.2.1 Increasing government focus on disease prevention to drive market 267
14.4.3 JAPAN 272
14.4.3.1 Stringent safety laws and foodborne outbreaks to fuel uptake 272
14.4.4 INDIA 276
14.4.4.1 High target patient population to boost demand 276
14.4.5 SOUTH KOREA 280
14.4.5.1 Favorable government initiatives for medical tourism to support market growth 280
14.4.6 AUSTRALIA 284
14.4.6.1 Favorable healthcare automation techniques to support market growth 284
14.4.7 REST OF ASIA PACIFIC 288
14.5 LATIN AMERICA 291
14.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK 292
14.5.2 BRAZIL 297
14.5.2.1 Improving healthcare infrastructure and stringent regulations to fuel market 297
14.5.3 MEXICO 301
14.5.3.1 Increasing prevalence of HIV to drive market 301
14.5.4 REST OF LATIN AMERICA 304
14.6 MIDDLE EAST & AFRICA 308
14.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK 310
14.6.2 SAUDI ARABIA 314
14.6.2.1 Increasing focus on healthcare automation to drive market 314
14.6.3 UNITED ARAB EMIRATES (UAE) 318
14.6.3.1 Improvements in healthcare infrastructure to support market growth 318
14.6.4 REST OF MIDDLE EAST & AFRICA 322
15 COMPETITIVE LANDSCAPE 326
15.1 INTRODUCTION 326
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 326
15.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN RAPID MICROBIOLOGY TESTING MARKET 326
15.3 REVENUE ANALYSIS, 2023–2025 328
 
15.4 MARKET SHARE ANALYSIS, 2025 328
15.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025 329
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 331
15.5.1 STARS 331
15.5.2 EMERGING LEADERS 331
15.5.3 PERVASIVE PLAYERS 331
15.5.4 PARTICIPANTS 331
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 333
15.5.5.1 Company footprint 333
15.5.5.2 Region footprint 334
15.5.5.3 Product footprint 335
15.5.5.4 Application footprint 335
15.5.5.5 End-user footprint 336
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 336
15.6.1 PROGRESSIVE COMPANIES 336
15.6.2 RESPONSIVE COMPANIES 336
15.6.3 DYNAMIC COMPANIES 337
15.6.4 STARTING BLOCKS 337
15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 338
15.6.5.1 Detailed list of key startups/SMEs 338
15.6.5.2 Competitive benchmarking of startups/SMEs 339
15.7 COMPANY VALUATION & FINANCIAL METRICS 340
15.7.1 FINANCIAL METRICS 340
15.7.2 COMPANY VALUATION 340
15.8 BRAND/PRODUCT COMPARISON 341
15.9 COMPETITIVE SCENARIO 341
15.9.1 PRODUCT LAUNCHES & APPROVALS 341
15.9.2 DEALS 342
15.9.3 EXPANSIONS 343
16 COMPANY PROFILES 344
16.1 KEY PLAYERS 344
16.1.1 BIOMÉRIEUX 344
16.1.1.1 Business overview 344
16.1.1.2 Products offered 346
16.1.1.3 Recent developments 348
16.1.1.3.1 Product launches & approvals 348
16.1.1.3.2 Deals 349
16.1.1.3.3 Other developments 350
16.1.1.4 MnM view 350
16.1.1.4.1 Right to win 350
 
16.1.1.4.2 Strategic choices 351
16.1.1.4.3 Weaknesses & competitive threats 351
16.1.2 WATERS CORPORATION 352
16.1.2.1 Business overview 352
16.1.2.2 Products offered 354
16.1.2.3 Recent developments 355
16.1.2.3.1 Product approvals 355
16.1.2.3.2 Deals 355
16.1.2.4 MnM view 356
16.1.2.4.1 Right to win 356
16.1.2.4.2 Strategic choices 356
16.1.2.4.3 Weaknesses & competitive threats 356
16.1.3 DANAHER CORPORATION 357
16.1.3.1 Business overview 357
16.1.3.2 Products offered 358
16.1.3.3 Recent developments 360
16.1.3.3.1 Product approvals 360
16.1.3.3.2 Deals 360
16.1.3.4 MnM view 361
16.1.3.4.1 Right to win 361
16.1.3.4.2 Strategic choices 361
16.1.3.4.3 Weaknesses & competitive threats 361
16.1.4 ABBOTT LABORATORIES 362
16.1.4.1 Business overview 362
16.1.4.2 Products offered 363
16.1.4.3 Recent developments 365
16.1.4.3.1 Product approvals 365
16.1.4.4 MnM view 365
16.1.4.4.1 Right to win 365
16.1.4.4.2 Strategic choices 365
16.1.4.4.3 Weaknesses & competitive threats 365
16.1.5 THERMO FISHER SCIENTIFIC INC. 366
16.1.5.1 Business overview 366
16.1.5.2 Products offered 367
16.1.5.3 Recent developments 369
16.1.5.3.1 Product launches 369
16.1.5.3.2 Deals 369
16.1.5.4 MnM view 370
16.1.5.4.1 Right to win 370
16.1.5.4.2 Strategic choices 370
16.1.5.4.3 Weaknesses & competitive threats 370
 
16.1.6 BRUKER CORPORATION 371
16.1.6.1 Business overview 371
16.1.6.2 Products offered 373
16.1.6.3 Recent developments 374
16.1.6.3.1 Product launches & approvals 374
16.1.6.3.2 Deals 374
16.1.7 QUIDELORTHO CORPORATION 375
16.1.7.1 Business overview 375
16.1.7.2 Products offered 376
16.1.7.3 Recent developments 378
16.1.7.3.1 Product launches & approvals 378
16.1.7.3.2 Deals 378
16.1.7.3.3 Expansions 379
16.1.8 SARTORIUS AG 380
16.1.8.1 Business overview 380
16.1.8.2 Products offered 382
16.1.9 MERCK KGAA 383
16.1.9.1 Business overview 383
16.1.9.2 Products offered 385
16.1.9.3 Recent developments 385
16.1.9.3.1 Product launches & approvals 385
16.1.10 F. HOFFMANN-LA ROCHE LTD 386
16.1.10.1 Business overview 386
16.1.10.2 Products offered 387
16.1.10.3 Recent developments 388
16.1.10.3.1 Product launches & approvals 388
16.1.10.3.2 Deals 388
16.1.11 CHARLES RIVER LABORATORIES, INC. 389
16.1.11.1 Business overview 389
16.1.11.2 Products offered 390
16.1.11.3 Recent developments 391
16.1.11.3.1 Product launches 391
16.1.11.3.2 Deals 391
16.1.12 NEOGEN CORPORATION 392
16.1.12.1 Business overview 392
16.1.12.2 Products offered 393
16.1.12.3 Recent developments 394
16.1.12.3.1 Product launches 394
16.1.13 BIO-RAD LABORATORIES, INC. 395
16.1.13.1 Business overview 395
16.1.13.2 Products offered 396
16.1.13.3 Recent developments 397
16.1.13.3.1 Product launches & approvals 397
16.1.13.3.2 Deals 397
16.1.14 SHIMADZU CORPORATION 398
16.1.14.1 Business overview 398
16.1.14.2 Products offered 400
16.1.14.3 Recent developments 400
16.1.14.3.1 Expansions 400
16.1.15 RAPID MICRO BIOSYSTEMS, INC. 401
16.1.15.1 Business overview 401
16.1.15.2 Products offered 402
16.1.15.3 Recent developments 403
16.1.15.3.1 Deals 403
16.2 OTHER PLAYERS 404
16.2.1 DON WHITLEY SCIENTIFIC LIMITED 404
16.2.2 GRADIENTECH 405
16.2.3 RQMICRO AG 406
16.2.4 COLIFAST AS 407
16.2.5 HYGIENA LLC 408
16.2.6 COPAN DIAGNOSTICS INC. 409
16.2.7 PERKINELMER INC. 410
16.2.8 HARDY DIAGNOSTICS 411
16.2.9 CHARM SCIENCES 412
16.2.10 R-BIOPHARM 413
17 RESEARCH METHODOLOGY 414
17.1 RESEARCH DATA 414
17.2 RESEARCH APPROACH 414
17.2.1 SECONDARY RESEARCH 415
17.2.1.1 Key data from secondary sources 416
17.2.2 PRIMARY DATA 417
17.2.2.1 Primary sources 417
17.2.2.2 Key data from primary sources 418
17.2.2.3 Key industry insights 419
17.3 MARKET SIZE ESTIMATION 420
17.3.1 BOTTOM-UP APPROACH 421
17.3.1.1 Approach 1: Company revenue estimation approach 421
17.3.1.2 Approach 2: Presentations of companies and primary interviews 422
17.3.1.3 Growth forecast 422
17.3.2 TOP-DOWN APPROACH 423
17.4 MARKET BREAKDOWN AND DATA TRIANGULATION 424
 
17.5 MARKET SHARE ANALYSIS 425
17.6 RESEARCH ASSUMPTIONS 425
17.6.1 PARAMETRIC ASSUMPTIONS 425
17.6.2 GROWTH RATE ASSUMPTIONS 426
17.7 RESEARCH LIMITATIONS 426
17.8 RISK ASSESSMENT 426
18 APPENDIX 427
18.1 DISCUSSION GUIDE 427
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 432
18.3 CUSTOMIZATION OPTIONS 434
18.4 RELATED REPORTS 434
18.5 AUTHOR DETAILS 435